Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma
AUTOR(ES)
Ai, Weiyun Z.
FONTE
American Society of Hematology
RESUMO
Previous studies demonstrated that vaccination-induced tumor-specific immune response is associated with superior clinical outcome in patients with follicular lymphoma. Here, we investigated whether this positive correlation extends to overall survival (OS). We analyzed 91 untreated patients who received CVP chemotherapy (cyclophosphamide, vincristine, and prednisone) followed by idiotype vaccination. Idiotype proteins were produced either by the hybridoma method or by expression of recombinant idiotype-encoding sequences in mammalian or plant-based expression systems. We found that achieving a complete response/complete response unconfirmed (CR/CRu) to CVP and making an anti-idiotype antibody are 2 independent factors that each correlated with longer OS at 10 years (89% vs 68% with or without a CR/CRu, P = .024; 90% vs 69% with or without tumor-specific antibody production; P = .027). In the subset of patients who received hybridoma-generated vaccines, we found that anti-idiotype production was even more highly associated with superior OS (P < .002); this was the case even in patients with a partial response (PR) to CVP (P < .001).
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2700314Documentos Relacionados
- Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine.
- Anti-idiotype monoclonal antibody elicits broadly neutralizing anti-gp120 antibodies in monkeys.
- Pretreatment with cyclosporine and anti-interleukin 2 receptor antibody abrogates the anti-idiotype response in rat recipients of cardiac allografts.
- Blocking of pregnancy in mice by immunization with anti-idiotype directed against monoclonal anti-progesterone antibody.
- Characterization of a monoclonal anti-idiotype antibody to human anti-factor VIII antibodies.